FDA Approves Corbus’ Extension Study of Scleroderma Drug Resunab
The U.S. Food and Drug Administration (FDA) approved Corbus Pharmaceuticals’ 12-month, open-label extension study of its ongoing Phase 2 clinical trial of Resunab for the treatment of diffuse cutaneous systemic sclerosis (scleroderma). The extension study aims to offer all participants the option of receiving Resunab after they complete the 84-day, Phase 2,…